OBJECTIVES/HYPOTHESIS: MK-2206 is an orally active, allosteric inhibitor of AKT, a component of the phosphatidylinositol-3 kinase (PI3K) pathway. The PI3K-AKT pathway is a downstream signaling pathway that has recently been found to play an important role in head and neck squamous cell carcinoma (HNSCC). The objective of this study is to examine the role AKT inhibition may play in treatment of HNSCC. STUDY DESIGN: In vivo and in vitro study. METHODS: Cell migration after 24-hour treatment with subtherapeutic doses of MK-2206 was assessed using an enzyme-linked immunosorbent assay in four HNSCC cell lines: CAL27, FaDu, SCC-1, and SCC-5. In vitro effect of MK-2206 on cell migration was assessed by making linear scratches in culture plates after cell lines were grown to confluency. Images were taken at 8, 16, and 24 hours. In vivo analysis was performed on nude mice with human SCC1-orthotopic tongue tumors. After tumors were allowed to grow for 7 days, mice were treated with oral dosing of 120 mg/kg of MK-2206 every other day for 2 weeks. Tumor size was assessed after each treatment using a pair of digital calipers. At the end of the treatment period, mice were sacrificed and cervical lymph nodes were assessed for metastasis using fluorescent imaging of tumor cell markers. RESULTS: Subtherapeutic doses of MK-2206 were sufficient to significantly reduce cell migration in FaDu, SCC-1, and SCC-5 cell lines (P < .001) but not in Cal27 (P = .09). In vitro scratch test results in SCC-1 cells yielded significant reduction in cell movement at 8, 16, and 14 hours (P < .001). In vivo orthotopic model yielded significant reduction in primary tumor size (P = .04) and reduction in positive cervical lymph nodes (P = .01) between treatment and control mice. In addition we found 100% survival of MK-2206 treated mice after 2 weeks of treatment compared with 70% survival in our control group (P = .03). CONCLUSIONS: Treatment with MK-2206 is sufficient to inhibit HNSCC chemotaxis and migration in vitro. In an orthotopic model, treatment with MK-2206 reduces primary tumor size and cervical metastasis while improving survival. MK-2206 currently is being used in phase II clinical trials for combination treatment of metastatic solid tumors and may be useful for treating HNSCC as well.
OBJECTIVES/HYPOTHESIS: MK-2206 is an orally active, allosteric inhibitor of AKT, a component of the phosphatidylinositol-3 kinase (PI3K) pathway. The PI3K-AKT pathway is a downstream signaling pathway that has recently been found to play an important role in head and neck squamous cell carcinoma (HNSCC). The objective of this study is to examine the role AKT inhibition may play in treatment of HNSCC. STUDY DESIGN: In vivo and in vitro study. METHODS: Cell migration after 24-hour treatment with subtherapeutic doses of MK-2206 was assessed using an enzyme-linked immunosorbent assay in four HNSCC cell lines: CAL27, FaDu, SCC-1, and SCC-5. In vitro effect of MK-2206 on cell migration was assessed by making linear scratches in culture plates after cell lines were grown to confluency. Images were taken at 8, 16, and 24 hours. In vivo analysis was performed on nude mice with humanSCC1-orthotopic tongue tumors. After tumors were allowed to grow for 7 days, mice were treated with oral dosing of 120 mg/kg of MK-2206 every other day for 2 weeks. Tumor size was assessed after each treatment using a pair of digital calipers. At the end of the treatment period, mice were sacrificed and cervical lymph nodes were assessed for metastasis using fluorescent imaging of tumor cell markers. RESULTS: Subtherapeutic doses of MK-2206 were sufficient to significantly reduce cell migration in FaDu, SCC-1, and SCC-5 cell lines (P < .001) but not in Cal27 (P = .09). In vitro scratch test results in SCC-1 cells yielded significant reduction in cell movement at 8, 16, and 14 hours (P < .001). In vivo orthotopic model yielded significant reduction in primary tumor size (P = .04) and reduction in positive cervical lymph nodes (P = .01) between treatment and control mice. In addition we found 100% survival of MK-2206 treated mice after 2 weeks of treatment compared with 70% survival in our control group (P = .03). CONCLUSIONS: Treatment with MK-2206 is sufficient to inhibit HNSCC chemotaxis and migration in vitro. In an orthotopic model, treatment with MK-2206 reduces primary tumor size and cervical metastasis while improving survival. MK-2206 currently is being used in phase II clinical trials for combination treatment of metastatic solid tumors and may be useful for treating HNSCC as well.
Authors: Caroline S Kim; Vasily V Vasko; Yasuhito Kato; Michael Kruhlak; Motoyasu Saji; Sheue-Yann Cheng; Matthew D Ringel Journal: Endocrinology Date: 2005-07-07 Impact factor: 4.736
Authors: Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal Journal: Curr Cancer Drug Targets Date: 2008-05 Impact factor: 3.428
Authors: John P Gleysteen; J Robert Newman; David Chhieng; Andra Frost; Kurt R Zinn; Eben L Rosenthal Journal: Head Neck Date: 2008-06 Impact factor: 3.147
Authors: Sanjeev Kumar; Christopher S Bryant; Sreedhar Chamala; Aamer Qazi; Shelly Seward; Jagannath Pal; Christopher P Steffes; Donald W Weaver; Robert Morris; John M Malone; Masood A Shammas; Madhu Prasad; Ramesh B Batchu Journal: Mol Cancer Date: 2009-04-22 Impact factor: 27.401
Authors: Brigette B Y Ma; Vivian W Y Lui; Connie W C Hui; Cecilia P Y Lau; Chi-Hang Wong; Edwin P Hui; Margaret H Ng; S W Tsao; Yan Li; Anthony T C Chan Journal: Invest New Drugs Date: 2012-11-11 Impact factor: 3.850
Authors: Peter Szaniszlo; Susan M Fennewald; Suimin Qiu; Carla Kantara; Tuya Shilagard; Gracie Vargas; Vicente A Resto Journal: Head Neck Date: 2014-01-27 Impact factor: 3.147
Authors: Ann Margaret V Chang; Marina N Nikiforova; Jonas T Johnson; Julie E Bauman; Bayardo Perez-Ordonez; Raja R Seethala; Jeffrey F Krane; Simion I Chiosea Journal: Head Neck Pathol Date: 2013-11-21
Authors: Jocelyn F Burke; Logan Schlosser; April D Harrison; Muthusamy Kunnimalaiyaan; Herbert Chen Journal: Ann Surg Oncol Date: 2013-07-31 Impact factor: 5.344
Authors: Cara B Gonzales; Jorge J De La Chapa; Pothana Saikumar; Prajjal K Singha; Nicholas F Dybdal-Hargreaves; Jeffery Chavez; Aaron M Horning; Jamie Parra; Nameer B Kirma Journal: Oral Oncol Date: 2016-08 Impact factor: 5.337
Authors: Tuhina Mazumdar; Lauren A Byers; Patrick Kwok Shing Ng; Gordon B Mills; Shaohua Peng; Lixia Diao; You-Hong Fan; Katherine Stemke-Hale; John V Heymach; Jeffrey N Myers; Bonnie S Glisson; Faye M Johnson Journal: Mol Cancer Ther Date: 2014-09-05 Impact factor: 6.261
Authors: Amanda Herzog; Yansong Bian; Robert Vander Broek; Bradford Hall; Jamie Coupar; Hui Cheng; Anastasia L Sowers; John D Cook; James B Mitchell; Zhong Chen; Ashok B Kulkarni; Carter Van Waes Journal: Clin Cancer Res Date: 2013-05-02 Impact factor: 12.531